Auriga Partners logo

Auriga Partners

Europe, Ile-de-France, France, Paris

Description

Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information

Investor Profile

Auriga Partners has made 162 investments, with 0 in the past 12 months and 20% as lead.

Stage Focus

  • Series B (28%)
  • Series A (23%)
  • Series Unknown (16%)
  • Series C (13%)
  • Series D (5%)
  • Post Ipo Equity (4%)
  • Seed (3%)
  • Series E (3%)
  • Private Equity (1%)
  • Corporate Round (1%)

Country Focus

  • France (65%)
  • United States (17%)
  • Switzerland (6%)
  • United Kingdom (4%)
  • Sweden (2%)
  • Pakistan (2%)
  • Israel (2%)
  • Belgium (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Manufacturing
  • Software
  • Medical Device
  • Therapeutics
  • Information Technology
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Auriga Partners frequently co-invest with?

Wellington Partners
Europe, Bayern, Germany, Munich
Co-Investments: 7
Innovation Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 11
Omnes Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 12
Ventech
Europe, Ile-de-France, France, Paris
Co-Investments: 12
Andera Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 13
Sofinnova Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 9
Rothschild & Co.
Europe, Ile-de-France, France, Paris
Co-Investments: 7
Idinvest Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 12
Bpifrance
Europe, Ile-de-France, France, Maisons-alfort
Co-Investments: 10
Siparex Groupe
Europe, Ile-de-France, France, Paris
Co-Investments: 13

Which angels does Auriga Partners often collaborate with?

Shared Deals: 1
JL
Europe, France
Shared Deals: 1
AS
Europe, Midi-Pyrenees, France, Toulouse
Shared Deals: 1

What are some of recent deals done by Auriga Partners?

Exeliom

Dijon, Bourgogne, France

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.

BiopharmaBiotechnologyHealth CarePharmaceutical
Series AJun 30, 2023
Amount Raised: $8,733,148
Patrowl

Paris, Ile-de-France, France

Patrowl helps you to identify and harden you External Security Posture with realtime and continuous Pentest-as-a-Service solution

Cyber SecurityPenetration Testing
SeedJun 24, 2022
Amount Raised: $2,111,199
Vade Secure

Hem, Picardie, France

Vade Secure offers an email filtering service against phishing, malware, spear phishing, and spam.

Cyber SecurityEmailEnterprise SoftwareInformation TechnologySecuritySoftware
Series UnknownMay 31, 2022
Amount Raised: $30,055,560
Exeliom

Dijon, Bourgogne, France

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.

BiopharmaBiotechnologyHealth CarePharmaceutical
Series AJul 6, 2018
Amount Raised: $8,227,454
Flash Therapeutics

Toulouse, Midi-Pyrenees, France

Flash Therapeutics is a new gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform.

BiotechnologyHealth CareMedical
Private EquityMay 16, 2018
Amount Raised: $3,898,889
EnobraQ

Ramonville-saint-agne, Midi-Pyrenees, France

EnobraQ is a Toulouse-based biotechnology company.

BiotechnologyChemical
SeedApr 10, 2018
Amount Raised: $3,585,235
Pherecydes Pharma

Romainville, Ile-de-France, France

Pherecydes Pharma Operator of an innovative biotechnologies company created to develop personalized phage therapy.

BiotechnologyHealth CareMedical Device
Series BJan 16, 2018
Amount Raised: $10,675,921
aveni

Massy, Ile-de-France, France

Aveni offers novel metallization technology that enables the future of semiconductor manufacturing.

ElectronicsManufacturingSemiconductor
Series BOct 24, 2017
Amount Raised: $10,466,463
Vectalys

Toulouse, Midi-Pyrenees, France

Vectalys help scientists understand cellular and molecular mechanisms in order to discover new drugs and therapies.

BiotechnologyManufacturingWellness
Series UnknownJun 13, 2017
Amount Raised: $1,681,407
VitaDX

Paris, Ile-de-France, France

VitaDX develops a non-invasive solution for early bladder cancer diagnosis.

Artificial Intelligence (AI)BiotechnologyOncology
SeedJun 6, 2017
Amount Raised: $1,803,359